151 related articles for article (PubMed ID: 8194433)
21. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
22. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones.
Ide H; Fujiya S; Aanuma Y; Agishi Y
Clin Ther; 1990; 12(5):410-20. PubMed ID: 2268863
[TBL] [Abstract][Full Text] [Related]
23. [Effect of xuezhikang on the treatment of primary hyperlipidemia].
Kou W; Lu Z; Guo J
Zhonghua Nei Ke Za Zhi; 1997 Aug; 36(8):529-31. PubMed ID: 10436958
[TBL] [Abstract][Full Text] [Related]
24. Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Neuman MP; Neuman HR; Neuman J
Atherosclerosis; 1991 Dec; 91 Suppl():S11-9. PubMed ID: 1789812
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Tikkanen MJ; Laakso M; Ilmonen M; Helve E; Kaarsalo E; Kilkki E; Saltevo J
Diabetes Care; 1998 Apr; 21(4):477-81. PubMed ID: 9571327
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients.
Shidfar F; Keshavarz A; Jallali M; Miri R; Eshraghian M
Int J Vitam Nutr Res; 2003 May; 73(3):163-70. PubMed ID: 12847992
[TBL] [Abstract][Full Text] [Related]
27. Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol.
Hung YJ; Pei D; Wu DA; Kuo SW; Fuh MM; Jeng C
J Formos Med Assoc; 1999 Feb; 98(2):104-10. PubMed ID: 10083765
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
[TBL] [Abstract][Full Text] [Related]
29. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC
Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085
[TBL] [Abstract][Full Text] [Related]
30. [The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia].
Jian J; Hao X; Deng C; Zhou H; Lin J
Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):517-9. PubMed ID: 11798687
[TBL] [Abstract][Full Text] [Related]
31. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
[TBL] [Abstract][Full Text] [Related]
32. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients.
Azzarito C; Boiardi L; Zini M; Agosti A; Dotti C; Biagi R; Portioli I
Metabolism; 1992 Feb; 41(2):148-53. PubMed ID: 1310516
[TBL] [Abstract][Full Text] [Related]
33. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H
J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
[TBL] [Abstract][Full Text] [Related]
34. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients.
Hanes DS; Nicholson PG; Raval DD; Hooper FL; Behrens MT; Weir MR
Am J Ther; 1997; 4(2-3):85-91. PubMed ID: 10423597
[TBL] [Abstract][Full Text] [Related]
35. Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
Ziegler O; Drouin P
Cardiology; 1990; 77 Suppl 4():50-7. PubMed ID: 2073672
[TBL] [Abstract][Full Text] [Related]
36. The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia.
Ye P; Shang Y; Ding X
Chin Med Sci J; 2003 Mar; 18(1):9-13. PubMed ID: 12901521
[TBL] [Abstract][Full Text] [Related]
37. Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Ashraf R; Amir K; Shaikh AR
J Pak Med Assoc; 2005 Aug; 55(8):324-7. PubMed ID: 16164158
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.
Lim MC; Foo WM
Ann Acad Med Singap; 1992 Jan; 21(1):34-7. PubMed ID: 1590653
[TBL] [Abstract][Full Text] [Related]
39. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Feussner G; Eichinger M; Ziegler R
Clin Investig; 1992 Nov; 70(11):1027-35. PubMed ID: 1472833
[TBL] [Abstract][Full Text] [Related]
40. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.
Hutchesson AC; Moran A; Jones AF
J Clin Pharm Ther; 1994 Dec; 19(6):387-9. PubMed ID: 7876371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
